Yazar "Boruban, Cem" seçeneğine göre listele
Listeleniyor 1 - 17 / 17
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Acidosis might make breast cancer cells more susceptible to metastasize by shifting CXCL12 monomer-dimer equilibrium to monomeric state(CHURCHILL LIVINGSTONE, 2005) Altundağ, Kadri; Altundağ, Özden; Altundağ, Muzaffer Bedri; Boruban, Cem[Abstract not Available]Öğe Activation patterns of epidermal growth factor-receptor signaling in glioblastoma multiforme: In regard to Chakravarti et al. (Int J Radiat Oncol Biol Phys 2005;62 : 318-327)(ELSEVIER SCIENCE INC, 2005) Altundağ, Kadri; Altundağ, Özden; Gündüz, Esra; Boruban, Cem[Abstract not Available]Öğe The acute effect of tropisetron on ECG parameters in cancer patients(SPRINGER, 2008) Yavas, Ozlem; Yazici, Mehmet; Eren, Onder; Boruban, Cem; Artac, Mehmet; Genc, MineObjectives The 5-hydroxytryptamine 3 receptor antagonists, including tropisetron, ondansetron, granisetron, and dolasetron are agents used effectively for supportive care. They are used for the prevention and treatment of chemotherapy and radiotherapy-induced emesis. Despite their overall excellent safety profile, some electrocardiographic changes related to heart rate and repolarization were reported. Ondansetron, granisetron, and dolasetron were studied on this manner. But to our knowledge, there is no information about the cardiac side effects of tropisetron. In this study, we aimed to determine the acute effects of tropisetron on ECG parameters related to repolarization, heart rate, and systemic blood pressure. Materials and methods Fifty-five cancer patients who received tropisetron for the prevention of acute chemotherapy-induced nausea and vomiting were enrolled into this single center, prospective study. Standard 12-lead ECG recordings were performed at baseline and 30 min after tropisetron (5 mg given over 1 min IV bolus) administration. P wave durations and corrected QT intervals were measured; P wave dispersion and QTc dispersion were calculated. Results In comparison with baseline, mean heart rate significantly decreased 30 min after administration of tropisetron. Tropisetron did not result in a significant change in P wave duration, corrected QT interval, P dispersion, and QTc dispersion. Conclusion In this study, tropisetron did not show any ventricular and atrial arrhythmogenic effect because of repolarization abnormalities. Only it may cause a slight decrease in heart rate.Öğe Are all prognostic factors changing with time in breast cancer? New proposal for classification of prognostic factors as time-dependent and time-independent(CHURCHILL LIVINGSTONE, 2005) Altundağ, Kadri; Altundağ, Özden; Boruban, Cem; Altundağ, Muzaffer Bedri; Gündüz, Mehmet[Abstract not Available]Öğe Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer(ELSEVIER IRELAND LTD, 2005) Altundağ, Özden; Altundağ, Kadri; Boruban, Cem; Silay, Yavuz S.[Abstract not Available]Öğe The effects of trastuzumab, paclitaxel, and carboplatin on HER2-positive cancer stem cells that are isolated from primary breast cancer cultures: a preliminary report(AMER ASSOC CANCER RESEARCH, 2015) Artac, Mehmet; Kayadibi, Gozde; Ceylan, Ayca; Kars, Meltem Demirel; Artac, Hasibe; Cakir, Murat; Boruban, Cem[Abstract not Available]Öğe Hormone receptor status of primary tumor as a prognostic factor in patients with liver metastases from breast cancer treated with transcatheter arterial chemoembolization(BAISHIDENG PUBL GRP CO LTD, 2005) Altundağ, Kadri; Altundağ, Özden; Aktolga, Serdal; Yavaş, Özlem; Boruban, Cem[Abstract not Available]Öğe Imatinib may be useful in the management of patients with glioblastoma(CHURCHILL LIVINGSTONE, 2005) Boruban, Cem; Yavaş, Özlem; Altundağ, Muzaffer Bedri; Altundağ, Kadri[Abstract not Available]Öğe Lapatinib Plus Capecitabine for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience(Karger, 2012) Çetin, Bülent; Benekli, Mustafa; Öksüzoğlu, Berna; Koral, Lokman; Ulaş, Arife; Dane, Faysal; Türker, İbrahim; Kaplan, Mehmet A.; Koca, Doğan; Boruban, Cem; Yılmaz, Burçak; Sevinç, Alper; Berk, Veli; Işıkdoğan, Abdurrahman; Uncu, Doğan; Harputluoğlu, Hakan; Coşkun, Uğur; Büyükberber, SüleymanBackground: We investigated the clinical outcome of patients with brain metastases (BMs) from human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) treated with lapatinib and capecitabine (LC). Patients and Methods: A total of 203 patients with HER2+ MBC, who had progressed after trastuzumab-containing chemotherapy, were retrospectively evaluated in 11 centers between September 2009 and May 2011. 85 patients who had developed BMs before the initiation of treatment with LC were included. All patients had received prior cranial radiotherapy. All patients were treated with the combination of lapatinib (1,250 mg/day continuously) and capecitabine (2,000 mg/m(2) on days 1-14 of a 21-day cycle). Results: The median follow-up was 10.5 months (range 1-38 months). An overall response rate of 27.1% was achieved, including complete response in 2 (2.4%) and partial response in 21 (24.7%) patients. Median progression-free survival was 7 months (95% confidence interval (CI) 5-9), with a median overall survival of 13 months (95% Cl 9-17). The most common side effects were hand-foot syndrome (58.8%), nausea (55.3%), fatigue (48.9%), anorexia (45.9%), rash (36.5%), and diarrhea (35.4%). Grade 3-4 toxicities were hand-foot syndrome (9.4%), diarrhea (8.3%), fatigue (5.9%), and rash (4.7%). There were no symptomatic cardiac events. Conclusion: LC combination therapy was effective and well-tolerated in patients with HER2+ MBC with BMs, who had progressive disease after trastuzumab-containing therapy.Öğe Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience(KARGER, 2013) Cetin, Bulent; Benekli, Mustafa; Dane, Faysal; Boruban, Cem; Gumus, Mahmut; Oksuzoglu, Berna; Kaplan, Mehmet A.Background: The efficacy and safety of the lapatinib and capecitabine combination remain elusive in elderly patients with metastatic breast cancer (MBC), who progress after trastuzumab-based therapy. Patients and Methods: A total of 26 patients with HER2-positive MBC were included in this retrospective multicenter study. Median age was 69 years (range 65-82 years). All patients were treated with the combination of lapatinib (1,250 mg/day, continuously) and capecitabine (2,000 mg/m(2) on days 1-14 of a 21-day cycle). Data on demographics, clinical outcome, and toxicity were collected for descriptive analyses. Results: The median follow-up was 10 months (range 2-31 months). An overall response rate of 33.4% was achieved, including 1 complete response (3.8%), and 8 partial responses (30.8%). Median progression-free survival was 7 months (95% confidence interval (CI) 5-8), and the median overall survival was 15 months (95% CI 11-19). Most common side effects were fatigue (53.8%), diarrhea (46%), vomiting (36.3%), hand-foot syndrome (34.5%), and anorexia (34.6%). Grade 3-4 toxicities were identified as hand-foot syndrome (3.8%), diarrhea (7.6%), and fatigue (11.5%). There were no symptomatic cardiac events. Conclusion: Lapatinib and capecitabine combination therapy was effective and well tolerated in elderly patients with MBC, who had progressive disease after trastuzunnab-based therapy.Öğe Metastatic gastrointestinal stromal tumor with long-term response after treatment with concomitant radiotherapy and imatinib mesylate(LIPPINCOTT WILLIAMS & WILKINS, 2007) Boruban, Cem; Şencan, Orhan; Akmansu, Müge; Atik, Evrim Tunç; Özbek, SedaTotal surgical excision of the tumor is considered to be the only hope in treatment of malignant mesenchymal tumors. The roles of radiotherapy and/or chemotherapy have not yet been established. We report here a case of metastatic gastrointestinal stromal tumors with a dramatic long duration of response after treatment with concurrent radiotherapy and imatinib mesylate. The patient had a long-term complete response at the radiotherapy region with concomitant imatinib therapy although previous metastatic sides persisted with partial response.Öğe Phenytoin may increase the efficacy of temozolomide by methylating DNA-repair enzyme, O-6-methylguanine-DNA methyltransferase in patients with glioblastoma(CHURCHILL LIVINGSTONE, 2005) Altundağ, Özden; Altundağ, Kadri; Boruban, Cem; Altundağ, Muzaffer Bedri; Türen, Süleyman[Abstract not Available]Öğe Pure and mixed hormone receptor positive breast tumors: Are they different from therapeutic point of view?(CHURCHILL LIVINGSTONE, 2005) Altundağ, Kadri; Altundağ, Özden; Gündüz, Esra; Silay, Yavuz S.; Boruban, Cem[Abstract not Available]Öğe Recent findings for anti-metastatic potential of heparin(SAGE PUBLICATIONS INC, 2006) Altundağ, Kadri; Altundağ, Özden; Atik, Mustafa A.; Boruban, Cem; Altundağ, Muzaffer Bedri; Türen, Selahattin[Abstract not Available]Öğe The role of insulin-like growth factor-I receptor in the development of Herceptin resistance(AMER ASSOC CANCER RESEARCH, 2005) Altundağ, Kadri; Altundağ, Özden; Morandi, Paolo; Özçakar, Bülent; Boruban, Cem[Abstract not Available]Öğe Synchronous presentation of nasopharyngeal and renal cell carcinomas(Brazilian Society of Urology, 2006) Boruban, Cem; Yavaş, Özlem; Altundağ, Kadri; Şencan, OrhanWe report a rare case of synchronous presentation of nasopharyngeal and renal cell carcinomas in a-50-year old male patient with long standing smoking history. The patient was initially presented with a diagnosis of nasopharyngeal carcinoma. During staging process, the abdominal computed tomography detected a right renal solid mass, 6.5 cm in diameter, originating from posterior portion of the right renal cortex. Right radical nephrectomy was performed and pathological examination revealed renal cell carcinoma. Smoking was thought to be a risk factor for both cancers. Systemic evaluation of kidney should not be discarded in patients diagnosed with nasopharyngeal carcinoma living in western countries with a smoking history.Öğe Weekly paclitaxel may improve locoregional recurrence by decreasing interstitial fluid pressure in operable node-positive breast cancer patients(CHURCHILL LIVINGSTONE, 2006) Altundağ, Kadri; Altundağ, Özden; Boruban, Cem; Altundağ, Muzaffer Bedri; Türen, Selahattin[Abstract not Available]
